PINNACLE ASSOCIATES LTD - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
PINNACLE ASSOCIATES LTD ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3,656,774
+65.2%
197,237
-1.4%
0.07%
+78.9%
Q2 2023$2,213,316
-21.1%
200,119
-4.2%
0.04%
-33.3%
Q1 2023$2,804,171
+9.4%
208,799
+0.7%
0.06%
+1.8%
Q4 2022$2,563,967
-13.5%
207,273
-2.5%
0.06%
-17.6%
Q3 2022$2,965,000
+88.7%
212,548
+86.8%
0.07%
+100.0%
Q2 2022$1,571,000
-15.7%
113,770
-0.6%
0.03%
+3.0%
Q1 2022$1,863,000
-3.6%
114,494
-3.5%
0.03%0.0%
Q4 2021$1,932,000
+7.7%
118,604
-1.8%
0.03%0.0%
Q3 2021$1,794,000
-27.0%
120,805
-1.8%
0.03%
-25.0%
Q2 2021$2,456,000
-11.5%
122,960
+2.3%
0.04%
-17.0%
Q1 2021$2,775,000
-16.1%
120,218
-10.2%
0.05%
-20.9%
Q4 2020$3,306,000
-44.1%
133,828
-6.2%
0.07%
-52.1%
Q3 2020$5,913,000
-16.5%
142,612
-3.5%
0.14%
-20.0%
Q2 2020$7,083,000
-25.2%
147,832
-1.7%
0.18%
-39.2%
Q1 2020$9,470,000
-56.2%
150,412
-13.7%
0.29%
-39.1%
Q4 2019$21,598,000
+70.2%
174,293
-8.8%
0.47%
+58.2%
Q3 2019$12,687,000
+22.8%
191,188
+47.3%
0.30%
+23.6%
Q2 2019$10,329,000
-35.1%
129,815
-8.7%
0.24%
-32.6%
Q1 2019$15,905,000
+7.9%
142,188
-2.8%
0.36%
-5.8%
Q4 2018$14,742,000
-23.9%
146,268
-4.6%
0.38%
-5.2%
Q3 2018$19,378,000
+30.0%
153,358
-13.7%
0.40%
+30.9%
Q2 2018$14,905,000
+17.4%
177,635
-13.9%
0.31%
+23.3%
Q1 2018$12,700,000
+1.0%
206,430
-4.1%
0.25%
+2.9%
Q4 2017$12,577,000215,2900.24%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders